| abstract |
The present disclosure provides methods of treating pyogenic granulomas in a subject in need thereof. In some embodiments, the methods comprise topically administering, at least once daily, to a skin area of the subject affected by the pyogenic granuloma: a pharmaceutical composition comprising a pharmaceutically effective amount of allantoin and a pharmaceutically acceptable carrier. In certain embodiments, the administration the pharmaceutical composition provides a significant reduction in the size of the pyogenic granuloma within 2 weeks, 1 month, 2 months, or 3 months after the initial administration of the pharmaceutical composition. |